ArticleMolecular neurobiology2025
Ox-LDL Induces Neuron Apoptosis and Worsens Neurological Outcomes in aSAH via Fas/FADD Pathway.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The aim of this study was to assess the role of Ox-LDL (oxidized low-density lipoprotein) in the clinical prognosis of patients with aneurysmal subarachnoid hemorrhage (aSAH) and to investigate the underlying mechanisms in a mouse model of aSAH. Plasma Ox-LDL levels were measured in 50 aSAH patients and in 20 control patients via ELISA. Analysis of the associations between Ox-LDL levels and neurological function was carried out 1 year after discharge. The effects of Ox-LDL on aSAH model behavior and neurological damage were studied via Nissl staining and brain assessments. qRT‒PCR, Western blotting, and FITC/PI apoptosis detection were performed in an aSAH cell model to reveal the effects of Ox-LDL on neurons. Protein docking and Fas knockdown were used to explore the role of the Fas/FADD pathway in the Ox-LDL-induced exacerbation of neuron dysfunction. Among aSAH patients, those with lower Ox-LDL levels (1.755 ± 0.2107 mmol/L) had an mRS score ≤ 2 after one year, whereas those with higher Ox-LDL levels (2.532 ± 0.1860 mmol/L) had an mRS score > 2. Mice that were injected twice weekly with 0.2 ml of Ox-LDL, seven times, experienced increased neurological damage and neuronal apoptosis, activating the Fas/FADD pathway, an effect that was mirrored in the 20 µg/ml Ox-LDL-treated cell model. Blocking Fas/FADD with 170 µg of C75 or siRNA inhibited the apoptotic phenotype both in vivo and in vitro. Ox-LDL promoted neuronal apoptosis via Fas/FADD pathway after aSAH. The inhibition of Ox-LDL could serve as a therapeutic strategy to prevent neuronal damage after aSAH and improve prognostic outcomes.
Indexed as
Identifiers
40199806What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.